Cite
HARVARD Citation
Lucas, K. et al. (n.d.). Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results. Digestive and liver disease. pp. e38-. [Online].